Intas to pay €42M upfront in Henlius deal; Kymera gets $40M milestone; Pluvicto no longer in short supply
License out/inADCDrug Approval
Plus, news from Vicore, Elevate Bio, Monte Rosa Therapeutics and Angitia:
Intas, Henlius ink another deal:
Intas
said
Friday it plans to pay €42 million upfront to license Shanghai Henlius Biotech’s anti-PD-1 monoclonal antibody in Europe and India for specific indications. The terms also include up to €43 million in regulatory milestones and up to €100 million in sales milestones, plus royalties. The companies expect serplulimab to gain approval in small cell lung cancer in Europe in the first half of next year. The companies are already engaged in several agreements, including one set up in 2018 between Henlius and Accord Healthcare, an Intas subsidiary. —
Jaimy Lee
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.